Page last updated: 2024-12-04

puromycin aminonucleoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine : Puromycin derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6020
CHEMBL ID1233071
CHEBI ID42839
SCHEMBL ID346679
MeSH IDM0018175

Synonyms (43)

Synonym
brn 0093902
nsc 3056
einecs 200-388-3
CHEMBL1233071
stylomycin aminonucleoside
puromycin aminonucleoside ,
58-60-6
6-dimethylamino-9-(3'-ribosylamine)purine
aminonucleoside
puromycin, aminonucleoside
nsc-3056
3'-amino-3'-deoxy-n6,n6-dimethyladenosine
(2r,3r,4s,5s)-4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3-ol
adenosine, 3'-amino-3'-deoxy-n,n-dimethyl-
9-(3-amino-3-deoxy-.beta.-d-ribofuranosyl)-n,n-dimethyl-9h-purin-6-amine
pans
GMC ,
6n-dimethyl-3'-deoxy-amino-adenosine
(2r,3r,4s,5s)-4-amino-2-[6-(dimethylamino)-9h-purin-9-yl]-5-(hydroxymethyl)tetrahydro-3-furanol
3'-amino-3'-deoxy-n(6),n(6)-dimethyladenosine
3'-amino-3'-deoxy-n,n-dimethyladenosine
CHEBI:42839 ,
S9631
4-26-00-03697 (beilstein handbook reference)
unii-0q580u88v8
0q580u88v8 ,
EPITOPE ID:140946
6-dimethylamino-9-(3-amino-3-deoxyribosyl)purine
9-(3-amino-3-deoxy-.beta.-d-ribofuranosyl)-6-(dimethylamino)-9h-purine
6-(dimethylamino)-9-(3-amino-3-deoxy-.beta.-d-ribofuranosyl)purine
HY-15695
CS-1551
SCHEMBL346679
DTXSID7037264
mfcd00063462
puromycin aminonucleoside, 6-dimethylamin-9-[3'-amino-3'deoxyribosyl]-purine
AKOS030526166
(2r,3r,4s,5s)-4-amino-2-(6-(dimethylamino)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-ol
Q27120494
AT25062
EX-A4156
nsc 3056nsc 3056
GLXC-25758

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This is consistent with the hypothesis that the infiltrating renal macrophage, in large part, directly mediates the adverse effects of hypercholesterolemia in this model."( Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis.
Diamond, JR; Ding, G; Frye, J; Pesek-Diamond, I, 1992
)
0.28
" The toxic substance(s) was heat-stable and was extracted in the lipid fraction."( Cytotoxicity of sera from rats with puromycin aminonucleoside nephrosis.
Igawa, Y; Nakao, N; Natori, Y, 1996
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" In rats with proteinuria following the single iv injection of puromycin aminonucleoside, human albumin was removed from serum with a half-life of 17."( Renal clearance of human and rat albumins in the rat.
Gaizutis, M; Pesce, AJ; Pollak, VE, 1975
)
0.25

Bioavailability

ExcerptReferenceRelevance
" We found an increase in CsA bioavailability in the nephrotic group compared with controls."( Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats.
Castañeda-Hernández, G; Medeiros, M; Muñoz-Arizpe, R; Pedraza-Chaverri, J; Pérez-Urizar, J, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR."( Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.
Brown, AD; Chiu, PJ, 1981
)
0.26
" 70C and 360C were dosed to female Wistar rats at 100 mg/kg po daily for 7 days."( Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome.
Evans, GO; Goodwin, DA; Hawksworth, GM; Hodgson, ST; Morley, TJ; Read, NG, 1997
)
0.3
" Similarly, 14-day dosing of torbafylline resulted in a 3-fold decrease in urinary protein excretion."( Role of neutrophils and macrophages in experimental nephrosis of the rat.
Berens, KL; Luke, DR; Verani, RR, 1998
)
0.3
" Urine samples were collected for 24 h prior to dosing and at 8, 24, and 32 h postdosing."( Early indication of effects of puromycin aminonucleoside using a fluorimetric assay of 2-aminoacridone-derivatized carbohydrates in urine.
Birrell, H; Camilleri, P; Charlwood, J; Connelly, J; Tolson, D, 2000
)
0.31
" A PAN untreated control group (N= 7) was dosed with an isotype specific, null antibody."( Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.
Fogo, AB; Jha, S; Ledbetter, S; Ling, H; Ma, LJ; Pozzi, A, 2004
)
0.32
"These results show an in vivo dose-response with an agent that blocks the biologic activity of TGF-beta."( Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.
Fogo, AB; Jha, S; Ledbetter, S; Ling, H; Ma, LJ; Pozzi, A, 2004
)
0.32
" Male Sprague-Dawley rats were dosed via intraperitoneal injection once daily for mercuric chloride and amphotericin (up to 7 doses), while a single dose was given for all other compounds."( Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers.
Afshari, CA; Bass, MB; Cosenza, ME; Fitzpatrick, VD; Galambos, E; Healy, L; Hu, R; Nordone, PJ; Sullivan, L; Thukral, SK, 2005
)
0.33
"7% at an optimal bFGF dosage of 10 ng/ml."( Cell cycle re-entry sensitizes podocytes to injury induced death.
Amann, K; Daniel, C; Hagen, M; Kosel, A; Pfister, E; Pippin, J; Shankland, S, 2016
)
0.43
" Moreover, in vivo fluorescence molecular imaging showed that BSA633-MP was mainly accumulated in the liver and kidney after intravenous dosing for 24 h."( Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytes.
Chen, M; Mao, H; Qian, J; Wang, N; Wu, L; Xing, C; Zhang, B; Zhao, X, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
3'-deoxyribonucleoside
adenosinesAny purine ribonucleoside that is a derivative of adenosine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1584767Antiparasitic activity against Trypanosoma cruzi Tulahuen intracellular amastigotes by beta-galactosidase reporter gene assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (846)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990312 (36.88)18.7374
1990's207 (24.47)18.2507
2000's166 (19.62)29.6817
2010's142 (16.78)24.3611
2020's19 (2.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.34%)5.53%
Reviews14 (1.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other857 (98.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]